Biomarker Test:Liquid Biopsy Screening for Preterm Birth Prediction
Research type
Research Study
Full title
Biomarker Analysis in liquid BiopsY: Screening Test for Early Prediction of Preterm birth - (BABYSTEPP)
IRAS ID
336828
Contact name
Patrick Kierkegaard
Contact email
Sponsor organisation
Imperial College London
Clinicaltrials.gov Identifier
1500, BABYSTEPP- Biomarker Analysis in liquid BiopsY: Screening Test for Early Prediction of Preterm birth
Duration of Study in the UK
0 years, 9 months, 1 days
Research summary
A research team at Imperial College London has created a blood test that can help doctors spot pregnant women who might give birth early. This test can be used starting from the 12th week of pregnancy, enabling closer monitoring of these women. Prompt diagnosis and treatment for pregnant women are crucial, as premature babies are more likely to face health issues and even death. They have conducted further research that validated the effectiveness of this test, demonstrating its potential to reduce the risk of premature birth.
In a 9-month period, our focus is on working closely with various groups, including pregnant adults, parous adults (non-pregnant), clinicians, non-clinical NHS adoption decision-makers, and lab technicians, to find the best ways to integrate this test into standard healthcare practices. By using different qualitative research methods, we will identify what might make it easy or difficult for people to use this test and address any concerns they may have. Our ultimate goal is to smoothly incorporate this new test into current healthcare practices.REC name
London - Fulham Research Ethics Committee
REC reference
24/LO/0795
Date of REC Opinion
25 Nov 2024
REC opinion
Further Information Favourable Opinion